Savara Inc. (SVRA) Stock Ticker
SVRA right now
Market factors today
Unlock the full SVRA picture
About Savara Inc.
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
SVRA stock facts
| Ticker symbol | SVRA |
| Exchange | NASDAQ Global Select |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $1.0B |
| CEO | Matthew Pauls |
| Employees | 70 |
| Headquarters | Yardley, PA, US |
| IPO date | 2017-04-28 |
| Website | www.savarapharma.com |
What you can see for SVRA on Tickr
Live SVRA price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the SVRA report.
Rankings
FAQ
What is the ticker symbol for Savara Inc.?
The ticker symbol for Savara Inc. is SVRA, listed on the NASDAQ Global Select.
What is SVRA?
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main…